Myelodysplastic syndrome
Not recruitingStudy on the Safety and Effectiveness of Azacitidine and Venetoclax for Untreated Higher-Risk Myelodysplastic Syndromes Not Eligible for Transplant
Study on the Safety and Effectiveness of Azacitidine and Venetoclax for Untreated Higher-Risk Myelodysplastic Syndromes Not Eligible for Transplant
- Disease:Myelodysplastic syndrome
- Substances:AzacitidineVenetoclax
France- Participants:18–64 years · 65+ years
- Substances:Azacitidine
- Sponsor:Groupe Francophone Des Myelodysplasies









